PVCT
Provectus Biopharmaceuticals IncOTCQB
Healthcare • Biotechnology
Updated 2 days ago
Coverage ready
$0.07+3.58%
Close Jun 30, 2026
- Market cap
- —
- 1 month
- +6.8%
- 3 months
- +30.9%
- 1 year
- -7.5%
- 52-week range
- $0.04$0.10
- Dividend
- No dividends on record
- Short interest
- 0.2% of float801.2K shares · settled Sep 30, 2026 · 0.0% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Mar 31, 2026
- Revenue
- —
- Net income
- -$5.69M
- Free cash flow
- -$2.59M
- Book value
- —
- Total debt
- $2.65M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if PVCT is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
0 top institutions tracked
as of 2013-Q3 (filed 2013-11-15)
Note: 13F filings are reported up to 45 days after quarter-end.Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 1
Largest 13-F holders · Q2 2026
3 filers reported a long position in PVCT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| HOME FEDERAL BANK OF TENNESSEE | $6.9K | 100K | Unchanged |
| Atlas Wealth LLC | $1.4K | 19.6K | Unchanged |
| Financial Symmetry Inc | $707 | 10.2K | Unchanged |
Get the Full Analysis for PVCT
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.